Evidence map›Paper›PMID 40726965›Full record

ReviewActa biochimica Polonica2025

The rare disease burden: a multidimensional challenge.

Zuzanna Cyske, Edyta Radzanowska-Alenowicz, Estera Rintz, Lidia Gaffke, Karolina Pierzynowska

Abstract readReview
In one paragraph

Review in Acta biochimica Polonica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Advances in Therapies for Mucopolysaccharidoses.Current issues in molecular biology · 2026
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zuzanna CyskeDepartment of Molecular Biology, Faculty of Biology, University of Gdansk, Gdansk, Poland.
Edyta Radzanowska-AlenowiczFaculty of Social Sciences, University of Gdansk, Gdansk, Poland.
Estera RintzDepartment of Molecular Biology, Faculty of Biology, University of Gdansk, Gdansk, Poland.
Lidia GaffkeDepartment of Molecular Biology, Faculty of Biology, University of Gdansk, Gdansk, Poland.
Karolina PierzynowskaDepartment of Molecular Biology, Faculty of Biology, University of Gdansk, Gdansk, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although there no single, widely accepted definition of a "rare disease," this group of disorders includes conditions that affect only a small fraction of the population. A large number of rare diseases is caused by defined molecular defects, predominantly the occurrence of pathogenic variant(s) of genes. Thus, they are classified as "genetic diseases," among which there are many neurodegenerative disorders. Despite a low incidence of each such disease, majority of them are severe and no effective treatment is available. This creates a battery of problems for millions of people suffering from these disease as well as to their relatives and caregivers. However, the set of problems is larger; therefore, in this narrative review we summarize and discuss various kinds of problems caused by rare disease, including severe symptoms of patients, everyday problems of patients and caregivers, loneliness and social exclusion, diagnostic difficulties, unavailability of effective therapies and economic difficulties in introducing orphan drugs, and a complexity of studies on rare diseases due to low availability of biological material and complicated pathomechanisms. The global picture of the complex problems caused by rare diseases is presented.

Indexed as

Cost of IllnessRare DiseasesCaregiversHumansOrphan Drug Productiondiagnosticsmolecular causes of diseasesmultidisciplinary researchmultiple challengesrare diseasestreatment

Identifiers

PMID40726965
PMCPMC12301258

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.